Revenue surges 50%, but profit leverage fades: the margin recovery test
Revenue expanded sharply at 50.7% YoY to ₹125.9 Cr, validating capacity expansion and market demand. But PAT growth lagged at just 25.5%, with margins compressed 1.59 percentage points by cost inflation outpacing price pass-through. The entire growth narrative hinges on whether margin recovery materializes by Q4 FY27.
₹125.9 Cr
+50.7% YoY
₹12.8 Cr
+25.5% YoY, -23.5% QoQ
₹226.79 Cr
+30.3% from FY start
13.21%
-1.59 pp YoY
On the headline, Q2 FY27 delivers a revenue blowout: +50.7% YoY to ₹125.9 Cr, order book surging 30% to ₹226.79 Cr. But the profit story is a different film. PAT grew just 25.5% YoY — a 160 basis point gap vs. revenue growth — and fell 23.5% QoQ despite 14.4% sequential revenue increase. Margins compressed 1.59 percentage points YoY as raw material and energy costs spiked faster than price adjustments could spread. This is not a profitability quarter yet; it is a test of whether management's margin recovery promise for Q4 actually holds.
The margin problem: cost inflation outpaced pricing power
EBITDA margin fell from 14.80% (Q2 FY26) to 13.21% (Q2 FY27). Management attributed this to tungsten, ferroalloys, and energy cost spikes driven by geopolitical supply disruptions. Price increases were implemented, but with a documented 1–1.5 quarter lag on longer-lead orders (3–9 months) and fixed-price risk on short-lead items (under 6 months). Q2 is the lag quarter — older orders, priced before cost inflation, executed at margin-dilutive rates. Q3–Q4 should see recovery as the ₹226.79 Cr order book — much of which is repriced for new input levels — gradually executes at better margins.
Geopolitical uncertainties, disruption in global supply chains have resulted in an increase in input costs, particularly for certain raw materials and specialty ferroalloys and metals.
Management claims graded against the numbers
Revenue growth 50.7% YoY to ₹125.9 Cr
Delivered ₹125.9 Cr with 50.7% YoY growth (Q2 FY26 base ≈₹83.6 Cr). H1 FY27 revenue ₹236.04 Cr, +43.73% YoY, validates sustained demand.
Supported
Order book ₹226.79 Cr, up 30.3% from FY start
Order book ₹226.79 Cr (Sep 30, 2026) vs ₹174.1 Cr (Mar 31, 2026) = exactly 30.3% growth. Breakdown: HE ₹177 Cr, Wear Plates ₹124 Cr, Welding ₹24.9 Cr.
Supported
PAT +25.5% YoY, but margins compressed due to cost inflation
PAT ₹12.8 Cr YoY +25.5% (Q2 FY26 ≈₹10.2 Cr). EBITDA margin fell 1.59 pp. QoQ PAT fell 23.5% partly due to JV seasonal loss (Europe/UK holiday impact).
Supported, but raises execution flags
Cost pass-through lag 1–1.5 quarters; order book repriced
Short-lead items (<6 months) typically fixed-price; longer items (3–9 months) have price variation clauses. ₹226.79 Cr order book repriced for new input costs. Lag mechanism credible but recovery timeline unproven.
Plausible; execution pending
Growth guidance 20–25% annual (reaffirmed from ~20%)
Prior call indicated ~20% annual; Q2 reaffirmed and slightly expanded to 20–25%. Backed by ₹226.79 Cr order book and capacity expansion. No new capex or detailed timeline.
Supported but unlevered by margin recovery
What changed on this call
Growth guidance reaffirmed at 20–25% (slight upside from ~20%). New product roadmap quantified: shredders, rotors, vertical mills, Comcast rollers currently 1–2% of revenue; targeted 10–15% within 3 years. Margin recovery timeline explicit: commitment to revert to Q2 FY26 EBITDA (~14.8%) by Q4 FY27 via cost pass-through. International expansion accelerated: now 53 countries (nascent stage prior), Western Africa live (Ghana, Nigeria), US orders expected soon (tariffs easing), Philippines steady. These are material strategy upgrades on visibility, though execution proofs remain pending.
The street's view: waiting for margin recovery proof
Stock sits at ₹415.55, down 20.07% from all-time high ₹519.9, but up 91.67% from 52-week low ₹216.8. Trading near SMA20 (₹409.49, above), below SMA50 (₹431.99), above SMA200 (₹351.42). RSI 49.3 neutral. Institutional ownership light but growing: FII 0.72% (+31 bps QoQ), DII 8.41% (+28 bps QoQ), promoter locked 69.76%. Aug bulk deals balanced (no promoter fire sales). Market appears to be pricing caution — the 20% drawdown from ATH reflects skepticism on margin recovery, while neutral momentum signals no panic. Street is waiting for Q3–Q4 evidence before re-rating.
Revenue growth 50.7% YoY on strong market demand
Order book ₹226.79 Cr (+30%) provides 2–4 quarter forward visibility
Capacity expansion nearing completion; phased ramp expected H2+
International expansion to 53 countries and Western Africa live
EBITDA margin compressed 1.59 pp YoY, below guidance
PAT grew 25.5% YoY but fell 23.5% QoQ; no profit leverage
Cost pass-through lag (1–1.5Q) creates execution risk
JV seasonal loss in Q2; recovery assumed Q4 but unproven
New product revenue 1–2% of total; 10–15% three-year target unproven
Risks ranked by holder concern
Margin recovery delayed or incomplete by Q4 FY27
HighIf EBITDA margin doesn't revert to 14.8%, the growth-to-leverage narrative breaks. Input costs may not stabilize, or price pass-through may lag further. Results in multiple compression and earnings downside.
Cost inflation persists beyond Q4, outpacing pricing power
MediumTungsten, ferroalloys, energy already spiked. Geopolitical disruptions could sustain inflation. Fixed-price risk on short-lead items limits pass-through options. Margin expansion could stall.
Capacity ramp-up execution slips; timeline vague
Medium₹100 Cr capex nearing completion, but phased operationalization timeline not detailed. Delays push H2 contribution to FY28, leaving growth dependent solely on cost recovery.
New product revenue scaling to 10–15% target unproven
MediumShredders unordered; vertical mills early-stage (one cement order). Current 1–2%. Slower adoption lowers three-year revenue ceiling and delays new segment margin ramp.
Geopolitical and tariff delays (US, Middle East)
MediumUS orders deferred by tariffs (expected soon); Middle East war creates supply volatility. Order execution delays could push revenue to FY28, tightening near-term growth visibility.
JV/associate profitability cyclical and lumpy
LowQ2 JV loss seasonal (Europe/UK holidays); recovery assumed Q4. Lumpy consolidation impact on PAT can surprise. Abu Dhabi, Turkey stabilizing (per call), so long-term risk contained.
1 · Q3 EBITDA margin and cost pass-through proof
This is the gate. Does margin expand toward 13.8%–14%+ in Q3, validating the 1–1.5 quarter lag thesis? If margin stays flat or declines, recovery timeline breaks. Volume growth alone won't cure leverage without margin expansion.
2 · Order book repricing and execution velocity
Is the ₹226.79 Cr order book holding value (adjusted for new costs) or declining (pricing pressure)? Quarterly order book updates and orders-to-revenue ratio will signal if pass-through is sticking or customers pushing back.
3 · New product first orders and scaling
Watch for first commercial shredder orders and revenue ramp in H2. Current 1–2% contribution must visibly move to 3–5% for 10–15% three-year target to be credible. Product-specific gross margins are critical.
4 · Capacity utilization and operating leverage
Capacity expansion nearing completion. Are Q3–Q4 orders sufficient to push utilization meaningfully higher? Operating leverage (margin expansion from fixed-cost absorption) is the secondary lever after cost pass-through.
Diffusion Engineers delivered a revenue blowout in Q2 FY27 — 50.7% YoY growth to ₹125.9 Cr — and the ₹226.79 Cr order book validates execution capacity. But profit didn't keep pace. PAT grew just 25.5% YoY and fell 23.5% QoQ, squeezed by cost inflation outpacing price pass-through. This is not a profitability quarter; it is a test of management's margin recovery promise.
The bull thesis is clear: ₹226 Cr of repriced orders, capacity completing, cost spikes moderating by Q4. If true, margins revert to 14.8%+ and operating leverage amplifies growth. The bear thesis is equally simple: pass-through fails, capacity slips, or new products stall. Margins stay compressed. The valuation call hinges entirely on which scenario Q4 FY27 proves.
Verdict: Hold. Revenue growth is real. Order book is healthy. But margin recovery is the gate, and near-term risks are material. Stay with the position, but patience is required. The number to track from here is EBITDA margin in Q3 — it is the proof point for the entire growth thesis.
Informational and educational content only. Not investment advice.